Sanofi’s Rimonabant Off The European Market; CHMP Finds Risk Management Plan Does Not Adequately Address Depression
This article was originally published in The Pink Sheet Daily
Executive Summary
Acomplia use doubles risk of psychiatric disorders in overweight patients, European review finds.